Published in Oncology Business Week, June 27th, 2004
The U.S. Food and Drug Administration (FDA) has ended its 30-day review of the GlobeImmune's Investigational New Drug (IND) application for the GI-4000 product series, which paves the way for Phase I trial initiation. GlobeImmune's GI-4000 series is a class of targeted immunotherapy products under development for the treatment of a variety of cancers. This series was developed using a yeast-based immunotherapy platform and targets a protein called Ras that is mutated in a number of different types of tumors.
According to the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.